You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
PHILADELPHIA, PA, September 24, 2010 - Today Astellas Pharma US, Inc. ("Astellas") announced the Launch of the Appropriate Use Criteria (AUC) for Cardiac Radionuclide Imaging application (app) for...
Read more about New Smartphone App Launches For Cardiac Imaging Test
DEERFIELD, IL, September 15, 2010 – Astellas Pharma US, Inc. has announced the winners of the second 2010 Transplant Scholars Awards, which awarded a dozen $5,000 educational scholarships to...
SANTA MONICA, Calif.- Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a Phase I clinical trial of AGS-16M8F an antibody-drug conjugate...
Astellas Launches Science WoRx Program Aimed to Ignite Students' Passion for Science and Cultivate the Next Generation of Scientists Today Astellas Pharma US, Inc. ("Astellas") announced the...
Company Breaks Ground in Glenview, Will Create 150 Jobs GLENVIEW, IL – April 29, 2010. Governor Pat Quinn today announced an approximately $4 million investment package to assist Astellas Pharma...
Read more about Governor Quinn Announces Astellas Pharma U.S. Chooses Illinois for New Headquarters
MELVILLE, N.Y., Apr 29, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the...
MELVILLE, N.Y., Apr 26, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing...
First Maintenance Therapy Approved For a Broad Patient Population Including Squamous and Non- Squamous Histology MELVILLE, N.Y., Apr 16, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ:...
Survey Reveals Pervasive Donation Myths RICHMOND, Va. (April 5, 2010) – According to a new survey by Donate Life America, 43 percent of people are undecided, reluctant or do not wish to have...
MELVILLE, N.Y., Mar 19, 2010 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its international partner for Tarceva(R) (erlotinib), Roche, informed OSI that the...
Follow U.S. news
